Oncotarget

Research Papers:

Down-regulation of C12orf59 is associated with a poor prognosis and VHL mutations in renal cell carcinoma

Jun Xie, Chuangzhi Zhu, Jianting Wu, Cailing Li, Liya Luo, Lingling Xia, Xianxin Li, Yaoting Gui, Zhiming Cai and Zesong Li _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:6824-6834. https://doi.org/10.18632/oncotarget.6829

Metrics: PDF 1040 views  |   HTML 1183 views  |   ?  


Abstract

Jun Xie1,2,*, Chuangzhi Zhu2,*, Jianting Wu1,2, Cailing Li2, Liya Luo1, Lingling Xia1, Xianxin Li2, Yaoting Gui2, Zhiming Cai1, Zesong Li1

1Shenzhen Key Laboratory of Genitourinary Tumor, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China

2Peking University Shenzhen Hospital, Shenzhen 518036, China

*These authors have contributed equally to this work

Correspondence to:

Zesong Li, e-mail: lzssc@yahoo.com

Keywords: renal cell cancer (RCC), C12orf59, von Hippel-Lindau (VHL), prognosis, survival

Received: November 06, 2014     Accepted: December 26, 2015     Published: January 07, 2016

ABSTRACT

C12orf59 is newly identified gene in kidney. However, the relation of C12orf59 expression and clinic features is unknown. Here, our study showed that C12orf59 was broadly expressed in normal human tissues with high expression levels in kidney while its expression is beyond detectable in a panel of cancer cell lines. C12orf59 expression in RCC was significantly decreased compared with corresponding adjacent noncancerous tissues (P < 0.01). The decreased C12orf59 expression was correlated with lymph node status (P < 0.05), distant metastases (P < 0.05), poor survival (P < 0.001) (HR 3.00; 95% CI, 1.29–7.53), VHL non-sense mutations or frame-shift mutations (P < 0.01), and UMPP gene non-sense mutations or frame-shift mutations (P = 0.01). Thus, we propose that the decreased C12orf59 expression status is a prognostic biomarker of ccRCC and cooperates with the loss of VHL all the while promoting renal carcinogenesis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6829